News Overview

Bright Peak Therapeutics

Arianna Ramirez

Bright Peak Therapeutics AG is a pioneering Basel and San Diego-based biotech using a blend of chemical synthesis, protein engineering and recombinant technology to create and develop multifunctional immunotherapies for cancer and autoimmune diseases.  Our flexible technology platform allows us to conjugate enhanced cytokine “payloads” to existing antibodies and generate what we call “Bright Peak Immunoconjugates”. The company was spun out from the ETH Zürich in 2017 and is expecting to initiate clinical trials for BPT567 – a PD1-IL18 conjugate for cancer immunotherapy – later in 2024.


Bright Peak Therapeutics has successfully secured investment of 90 million US dollars after closing a Series C financing round. Read more here.

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.